Patents by Inventor Charles GUERIN

Charles GUERIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240182422
    Abstract: A method for preparing a compound of formula (I), a powder, and a pharmaceutical composition are disclosed. The method includes: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. In step (i), the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present. A powder including the composition of formula (I) may be obtained by the method. The powder may have a particle size distribution with specific D50, D90 and/or D10 values. A pharmaceutical composition may include the powder and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 23, 2022
    Publication date: June 6, 2024
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jérôme DENIS, Fabien DE BLASIO, Thierry BOYER, Charles GUERIN, Julien MICHAUX, Romain NAJMAN, Florence MAHUTEAU-BETZER
  • Patent number: 11872206
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: January 16, 2024
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 11617735
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: April 4, 2023
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 11576890
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: February 14, 2023
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 11559509
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: January 24, 2023
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Publication number: 20220409568
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Application
    Filed: June 28, 2022
    Publication date: December 29, 2022
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Publication number: 20220378736
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Application
    Filed: July 1, 2022
    Publication date: December 1, 2022
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Publication number: 20220362206
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Application
    Filed: June 28, 2022
    Publication date: November 17, 2022
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Publication number: 20210236455
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 5, 2021
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 10987337
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: April 27, 2021
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Publication number: 20200206182
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Application
    Filed: December 16, 2019
    Publication date: July 2, 2020
    Inventors: Bradford C. SIPPY, Raymond SKWIERCZYNSKI, Jean-Marie SCHNEIDER, Simon H. DROUIN, Charles GUERIN
  • Patent number: 4643384
    Abstract: A studio easel for selective tension or compression clamping of a canvas painting stretcher frame having top and bottom cross bars in fixed upright position at a desired level has a pair of elongated channel tracks for mounting upright in laterally spaced relation on a studio wall with a pair of opposed shoes slidable in each track. Grip locks on the shoes secure them to their tracks, a stretcher frame support on one shoe of each pair engages a cross bar of the frame. A push-pull clamp on the other shoe of the pair engages the opposite cross bar of the stretcher frame. The shoes are mounted for stretch clamping the frame by positioning the frame support shoe above the push-pull clamp shoes, hanging the top cross bar of the frame on the support shoes, engaging the bottom support frame with the push-pull clamps and pulling the clamps to stretch the frame.
    Type: Grant
    Filed: January 3, 1986
    Date of Patent: February 17, 1987
    Inventor: Charles A. Guerin